[Oncological treatment of patients with pancreatic cancer].
Only radical resection can cure patients with pancreatic cancer (PC); however, adjuvant gemcitabine (GEM) doubles the postoperative five-year-survival. The best treatment of locally advanced PC is not established, but radio-chemotherapy followed by surgery may be considered. Fit patients with metastatic PC benefit from GEM, which is standard. The addition of the epidermal growth factor-receptor-inhibitor erlotinib prolongs median survival significantly by two weeks and one-year survival by 7%. Very fit patients might benefit by combining GEM with platinum or capecitabine, but evidence is not firm. Participation in clinical trials is strongly encouraged in PC.
Ladekarl
Morten
M
Onkologisk Afdeling D, Arhus Sygehus, 8000 Arhus C, Denmark. mortlade@rm.dk
Jensen
Benny Vittrup
BV
Pfeiffer
Per
P
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine